Head-to-head · WeighScore
Ondra Health vs Teladoc Health
By GLP-1 ScorecardUpdated
Score comparison
Ondra Health has the higher recorded score — 86.8/100 to 55.9/100.
Ondra Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Ondra publishes monthly and prepaid compounded injection plans with pharmacy choices; compare the upfront bill, eligible pharmacy and early-cancellation repricing before choosing a term.
Before you choose
Teladoc Health does not publish a semaglutide price, so its Teladoc Health review sets out what it does disclose, while the Ondra Health review explains the conditions attached to Ondra Health's figure. The semaglutide cost page compares published rates across the field. Ask Teladoc Health for a written total before treating either one as the cheaper choice.
If neither one fits, Ondra Health vs TeleFirst Med and Sunlight.com vs Teladoc Health compare each of them with another graded program, and the list of alternatives to Ondra Health ranks the programs closest to Ondra Health on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.
Of the sellers that pay us a commission, the Belle Health review covers one graded close to these two, at 73.8/100. That relationship never changes a grade, and the review lists what we could not verify.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | Ondra Health | Teladoc Health |
|---|---|---|
| WeighScore | 86.8/100 | 55.9/100 |
| Grade | B | C |
| Site position | #5 | #461 |
| Semaglutide | $149/mo (compounded; month-to-month) | Not disclosed |
| Tirzepatide | $219/mo (compounded; month-to-month) | Not disclosed |
| Coverage | Advertises 50 states; pharmacy and formulation eligibility varies | Coverage not published |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Strengths
- Publishes monthly charges and separate upfront totals for longer plans
- Allows requests for an eligible pharmacy and formulation, subject to prescribing and availability
- Names independent clinical partners and advertises provider messaging, supplies and shipping
What to consider
- Six- and twelve-month plans require prepayment and an eligible Hallandale or Vials prescription
- Early prepaid cancellation reprices each three-month supply already sent at the regular quarterly rate
- Confirm the selected renewal cutoff and any earned consultation or administrative fees
- Branded and oral access, included lab testing and independent current certification were not established
Strengths
- Dedicated GLP-1 Prescription and Support program for weight management
- Backed by one of the largest virtual care companies in the US
- Partners with 50%-plus of Fortune 500 and 100-plus health plans
- Adds nutrition, coaching and connected device tracking
- Strong clinical credibility and brand trust
What to consider
- Distributed mainly via employers and health plans, limited direct cash-pay
- No transparent published monthly price for GLP-1 care
- Specific medications and eligibility vary by plan coverage
- Member experience can depend on the employer's chosen configuration
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.